Anti-EGFR antibody-drug conjugates and uses thereof
Exatecan-based antibody-drug conjugates targeting EGFR address the challenges of toxicity and instability in existing ADCs, achieving enhanced therapeutic efficacy in treating advanced or metastatic solid tumors by selective cancer cell delivery.
Patent Information
- Application Number
- PCT/US2026/028335
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Existing antibody-drug conjugates face challenges such as toxicity due to antibody binding to normal tissues and instability of the linker, leading to poor clinical efficacy and safety, particularly in delivering topoisomerase I inhibitors like exatecan for treating various cancers.
Development of exatecan-based antibody-drug conjugates, specifically targeting the epidermal growth factor receptor (EGFR), administered in controlled doses and formulations to enhance selective delivery to cancer cells, reducing systemic toxicity and improving therapeutic efficacy.
The exatecan-based antibody-drug conjugates demonstrate significant anti-tumor activity in preclinical models of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer, showing improved safety and efficacy by preferentially targeting EGFR-expressing tumors.
Smart Images

Figure US2026028335_19112026_PF_FP_ABST
Abstract
Description
Atty. Docket No. SMO-005WOANTI-EGFR ANTIBODY-DRUG CONJUGATES AND USES THEREOFCROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of, and priority to, U. S. Provisional Patent Application No. 63 / 806,863 filed on May 16, 2025, the content of which is hereby incorporated by reference herein in its entirety.BACKGROUND
[0002] Antibody-drug conjugates (ADC’s) provide a mechanism for selective delivery of small molecule therapeutic payloads to antigen-positive cancer cells, thereby attenuating systemic toxicity of cytotoxic drugs to antigen-negative normal cells. Three components of an ADC — the antibody, the cytotoxic payload, and the linker that joins them — are important in designing an effective therapeutic. Despite active development, challenges still exist, for example, toxicity due to the antibody binding to its target in normal tissue, and dispersion of the cytotoxic payload in normal tissue due to instability of the ADC linker. Thus, many ADC’s have not succeeded in clinical trials due to lack of safety and / or efficacy at tolerated doses.
[0003] Topoisomerase I plays a critical role in DNA replication in both normal and diseased conditions (e.g., cancer). As inhibition of topoisomerase I leads to cell death, compounds that bind to and inhibit topoisomerase I may be useful as therapeutic agents.
[0004] Camptothecin is a natural product with cytotoxic activity in a variety of cell lines. The binding of its active lactone ring to topoisomerase I inhibits DNA replication, thus causing cell apoptosis. However, its limitations for drug development include, for example, poor water solubility and an equilibrium between its active, lactone form and its inactive, ring-opened form.
[0005] Exatecan is a water-soluble camptothecin derivative. As a chemotherapeutic agent, exatecan mesylate did not gain drug approval after several clinical trials due to lack of efficacy or high toxicity at tested doses. Efforts to enable the clinical utility of exatecan have been made by converting exatecan into a prodrug form, where exatecan is covalently linked to a carboxymethyldextran polyalcohol polymer via a peptidyl spacer (a substrate for intracellular cathepsin proteases). However, this prodrug did not succeed in clinical trials.1IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0006] Thus, a need exists for compounds, for example antibody-drug conjugates, more amenable to clinical development and success in treating human tumors. Moreover, preferential delivery of topoisomerase I inhibitors to diseased tissues through antibody-drug conjugates could lead to improved safety and efficacy, thereby providing therapeutic options for a larger number of patients and types of cancers.SUMMARY
[0007] The present disclosure relates to methods and compositions that are useful for the treatment of cancer. The disclosure is directed, in part, to exatecan-based drug conjugates. For example, the present disclosure provides methods of using drug conjugates comprising a disclosed therapeutic payload, and the use of disclosed compounds as medicinal agents.
[0008] For example, disclosed herein is a method of treating a patient having advanced or metastatic solid cancer tumors in a patient in need thereof, comprising intravenously administering to the patient, once every two weeks or once every three weeks, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, or about 8 mg / kg of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein:n is an integer or a decimal from 7 to 8; andL is an anti-EGFR antibody.
[0009] Also disclosed herein is a method of treating a cancer selected from the group consisting of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer, in a patient in need thereof, comprising2IPTS / 200429160.1Atty. Docket No. SMO-005WOintravenously administering to the patient an effective amount of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein:n is an integer or a decimal from 7 to 8; andL is an anti-EGFR antibody.
[0010] Further disclosed herein is a method of treating a cancer selected from the group consisting of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer, in a patient in need thereof, comprising intravenously administering to the patient, once every two weeks or once every three weeks, about 1 mg / kg, about 2 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, or about 8 mg / kg of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein:n is an integer or a decimal from 7 to 8; andL is an anti-EGFR antibody.3IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0011] In addition, disclosed herein is method of treating a patient having advanced or metastatic solid cancer tumors selected from the group consisting of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer, and in need thereof, comprising intravenously administering to the patient, once every two weeks or once every three weeks, an aqueous pharmaceutical composition formulated for intravenous administration comprising:about 10 mg / mL of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein n is an integer or a decimal from 7 to 8, and L is an anti-EGFR antibody;about 20 mM histidine;about 8% sucrose (w / v); andabout 0.02% polysorbate 80 (w / v);wherein the pH of the composition is about 5.5 at room temperature.BRIEF DESCRIPTION OF THE DRAWINGS
[0012] FIG. 1 shows anti-tumor efficacy of Compound 5 in a MDA-MB-468, highEGFR expressing, triple negative breast cancer human tumor cell line-derived xenograft model.Tumor volume (mm3) of single intravenous dose of Compound 5 at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was monitored until between day 22-29 post dose. Data represented as mean ± SEM, n=12 / each data point.
[0013] FIG. 2 shows anti-tumor efficacy of Compound 5 in a FaDu. mid EGFR expressing, nasopharyngeal cancer human tumor cell line-derived xenograft model. Tumor4IPTS / 200429160.1Atty. Docket No. SMO-005WOvolume (mm3) of single intravenous dose of Compound 5 at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was monitored until between day 22-29 post dose. Data represented as mean ± SEM, n=12 / each data point.
[0014] FIG. 3 shows anti-tumor efficacy of Compound 5 in a CFPAC-1, low EGFR expressing, pancreatic ductal adenocarcinoma human tumor cell line-derived xenograft model. Tumor volume (mm3) of single intravenous dose of Compound 5 at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was monitored until between day 22-29 post dose. Data represented as mean ± SEM, n=12 / each data point.
[0015] FIG. 4 shows anti-tumor efficacy of Compound 5 in a HCC827, exonl9 del mutant, EGFR expressing, human non-small cell lung cancer cell line-derived xenograft model. Percent (%) tumor growth inhibition of single intravenous dose of Compound 5 at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was measured at day 28 post dose. Data represented as mean ± SEM, n=12 / each data point.
[0016] FIG. 5 shows anti-tumor efficacy of Compound 5 in a NCI-H1975, L858R / T790M double mutant, EGFR expressing, human non-small cell lung cancer cell line-derived xenograft model. Percent (%) tumor growth inhibition of Compound 5 treatment at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was measured at day 21 post dose. Data represented was mean ± SEM, n=12 / each data point.
[0017] FIG. 6 shows anti-tumor efficacy of Compound 5 in a COLO205, BRAF V600E-mutant, human colorectal adenocarcinoma cell line-derived xenograft model. Percent (%) tumor growth inhibition of treatment at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was measured at day 21 post dose. Data represented as mean + was SEM, n=12 / each data point.
[0018] FIG. 7 shows anti-tumor efficacy of Compound 5 in a HCT 116, KRAS G13D mutant, human colon cancer cell line-derived xenograft model. Percent (%) tumor growth inhibition of Compound 5 treatment at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was measured at day 25 post dose. Data represented as mean ± SEM, n=12 / each data point.5IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0019] FIG. 8 shows anti-tumor efficacy of Compound 5 in a colorectal cancer patient-derived organoid model. Percent (%) tumor growth inhibition of single dose and 3 doses of Compound 5 at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was measured at day 35 post first dose. Data was represented as mean ± SEM, n=12 / each data point.
[0020] FIG. 9 shows tumor suppression effect of antibody drug conjugate Compound 3 on human lung mucoepidermoid carcinoma cell line NCI-H292 and colon cancer cell line SW620-luc co-inoculated xenograft in NOD-SCID mice.
[0021] FIG. 10 shows tumor suppression effect of antibody drug conjugate Compound 4 on human lung mucoepidermoid carcinoma cell line NCI-H292 and colon cancer cell line SW620-luc co-inoculated xenograft in NOD-SCID mice.
[0022] FIG. 11 shows tumor suppression effect of antibody drug conjugate Compound3 on human lung adenocarcinoma cell line A549 xenograft in NOD-SCID mice at a dose level of3 mg / kg, 4 doses administered weekly.
[0023] FIG. 12 shows tumor suppression effect of antibody drug conjugate Compound4 on human lung adenocarcinoma cell line A549 xenograft in NOD-SCID mice at a dose level of 3 mg / kg, 4 doses administered weekly.
[0024] FIG. 13 shows tumor suppression effect of antibody drug conjugate Compound3 on human lung adenocarcinoma cell line A549 xenograft in NOD-SCID mice at a dose level of 10 mg / kg, 4 doses administered weekly.
[0025] FIG. 14 shows tumor suppression effect of antibody drug conjugate Compound4 on human lung adenocarcinoma cell line A549 xenograft in NOD-SCID mice at a dose level of 10 mg / kg, 4 doses administered weekly.
[0026] FIG. 15 shows tumor suppression effect of antibody drug conjugate Compound4 on human lung mucoepidermoid carcinoma cell line NCI-H292 in NOD-SCID mice at a dose level of 10 mg / kg, 1 dose.6IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0027] FIG. 16 shows tumor suppression effect of antibody drug conjugate Compound4 on human lung mucoepidermoid carcinoma cell line NCI-H292 in NOD-SCID mice at a dose level of 3 mg / kg, 3 doses.
[0028] FIG. 17 shows tumor suppression effect of antibody drug conjugate Compound4 on human pancreatic adenocarcinoma cell line CFPAC1 in Nu / Nu mice at a dose level of 1 mg / kg, 3 doses.
[0029] FIG. 18 shows tumor suppression effect of antibody drug conjugate Compound6 on human pancreatic adenocarcinoma cell line CFPAC1 in Nu / Nu mice at a dose level of 1 mg / kg, 3 doses.
[0030] FIG. 19 shows tumor suppression effect of antibody drug conjugate Compound 6 on human nasopharyngeal carcinoma cell line FaDu in Nu / Nu mice at a dose level of 1 mg / kg,3 doses.
[0031] FIG. 20 shows tumor suppression effect of antibody drug conjugate Compound4 on human triple negative breast cancer cell line MDA-MB-468 in NOD SCID mice at a dose level of 1 mg / kg, 3 doses.
[0032] FIG. 21 shows tumor suppression effect of antibody drug conjugate Compound6 on human triple negative breast cancer cell line MDA-MB-468 in Nu / Nu mice at a dose level of 1 mg / kg, 3 doses.DETAILED DESCRIPTION
[0033] The features and other details of the disclosure will now be more particularly described. Before further description of the present disclosure, certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and as understood by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.7IPTS / 200429160.1Atty. Docket No. SMO-005WODefinitions
[0034] As used herein and in the appended claims, the singular forms “a,” “an,” and“the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an agent” includes a plurality of such agents, and equivalents thereof known to those skilled in the art, and so forth. When ranges are used herein, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term “about” when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range, in some instances, will vary between 1% and 15% of the stated number or numerical range. The term “comprising” (and related terms such as “comprise” or “comprises” or “having” or “including”) is not intended to exclude that in other certain embodiments, for example, an embodiment of any composition of matter, composition, method, or process, or the like, described herein, “consist of’ or “consist essentially of’ the described features.
[0035] The terms “treat,” “prevent,” “ameliorate,” and “inhibit,” as well as words stemming therefrom, as used herein, do not necessarily imply 100% or complete treatment, prevention, amelioration, or inhibition. Rather, there are varying degrees of treatment, prevention, amelioration, and inhibition of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the disclosed methods can provide any amount of any level of treatment, prevention, amelioration, or inhibition of the disorder in a mammal. For example, a disorder, including symptoms or conditions thereof, may be reduced by, for example, about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, or about 10%. Furthermore, the treatment, prevention, amelioration, or inhibition provided by the methods disclosed herein can include treatment, prevention, amelioration, or inhibition of one or more conditions or symptoms of the disorder, e.g., cancer or an inflammatory disease. Also, for purposes herein, “treatment,” “prevention,” “amelioration,” or “inhibition” encompass delaying the onset of the disorder, or a symptom or condition thereof. “Treating” includes any effect, e.g., lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder and the like.8IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0036] “Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans. The compounds of the present disclosure can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like). “Modulation” includes antagonism (e.g., inhibition), agonism, partial antagonism and / or partial agonism.
[0037] The terms “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of a compound or composition (e.g., an oral tablet composition) disclosed herein being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated, e.g., cancer or an inflammatory disease. In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition comprising a compound disclosed herein required to provide a clinically significant decrease in disease symptoms. In some embodiments, an appropriate “effective” amount in any individual case is determined using techniques, such as a dose escalation study.
[0038] “Pharmaceutically or pharmacologically acceptable” include molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate. For human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologies standards.
[0039] The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” as used herein refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.9IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0040] The term “pharmaceutical composition” as used herein refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
[0041] The term “pharmaceutically acceptable salt(s)” as used herein refers to salts of acidic or basic groups that may be present in compounds used in the compositions. Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including, but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., l,l’-methylene- / ?z -(2-hydroxy-3-naphthoate)) salts. Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts, particularly calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts. Compounds included in the present compositions that include a basic or acidic moiety may also form pharmaceutically acceptable salts with various amino acids. The compounds of the disclosure may contain both acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case, the compound can exist as an acid addition salt, a zwitterion, or a base salt.
[0042] As will be understood by the skilled artisan, “H” is the symbol for hydrogen,“N” is the symbol for nitrogen, “S” is the symbol for sulfur, “O” is the symbol for oxygen. “Me” is an abbreviation for methyl. It will be appreciated that the present disclosure should be construed in congruity with the laws and principles of chemical bonding.
[0043] Procedures for making compounds described herein are provided below in the working examples and may be supplemented or substituted by procedures known to those of skill in the art. Starting materials used in the working examples can be purchased or prepared by methods described in the chemical literature, or by adaptations thereof, using methods known by10IPTS / 200429160.1Atty. Docket No. SMO-005WOthose skilled in the art. The order in which the steps are performed can vary depending on the groups introduced and the reagents used, but would be apparent to those skilled in the art.Disclosed compounds, or any of the intermediates described herein, can be further derivatized by using one or more standard synthetic methods known to those skilled in the art.Methods and Compositions
[0044] Disclosed herein, for example, is a method of treating a patient having advanced or metastatic solid cancer tumors in a patient in need thereof, comprising intravenously administering to the patient, once every two weeks or once every three weeks, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, or about 8 mg / kg of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein:n is an integer or a decimal from 7 to 8; andL is an anti-EGFR antibody.
[0045] For example, in some embodiments a method disclosed herein comprises administering the antibody-drug conjugate to the patient once every two weeks. In other embodiments, a method disclosed herein comprises administering the antibody-drug conjugate to the patient once every three weeks.
[0046] In further embodiments, a method disclosed herein comprises administering, for example, about 1 mg / kg, about 2 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, or about 8 mg / kg of the antibody-drug conjugate to the patient. In certain embodiments, a method disclosed herein comprises administering about 1 mg / kg of the antibody-drug conjugate to the patient.11IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0047] In some embodiments, the tumors are, for example, EGFR-expressing advanced or metastatic solid tumors. In some embodiments, the tumor is one or more of, for example, non- small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, colorectal cancer, cervical carcinoma, cutaneous squamous cell carcinoma, gastric cancer, ovarian cancer, pancreatic cancer, triple negative breast cancer, and urothelial transitional cell carcinoma. For example, in certain embodiments the tumor is one of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer.
[0048] Also disclosed herein is a method of treating a cancer selected from the group consisting of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer, in a patient in need thereof, comprising intravenously administering to the patient an effective amount of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein:n is an integer or a decimal from 7 to 8; andL is an anti-EGFR antibody.
[0049] In some embodiments, a method disclosed herein comprises intravenously administering the antibody-drug conjugate to the patient. In other embodiments, a method disclosed herein comprises administering the antibody-drug conjugate to the patient once every two weeks. In still other embodiments, a method disclosed herein comprises administering the antibody-drug conjugate to the patient once every three weeks.12IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0050] In additional embodiments, a method disclosed herein comprises administering, for example, about 1 mg / kg, about 2 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, or about 8 mg / kg of the antibody-drug conjugate to the patient. In certain embodiments, a method disclosed herein comprises administering about 1 mg / kg of the antibody-drug conjugate to the patient.
[0051] Further disclosed herein is a method of treating a cancer selected from the group consisting of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer, in a patient in need thereof, comprising intravenously administering to the patient, once every two weeks or once every three weeks, about 1 mg / kg, about 2 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, or about 8 mg / kg of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein:n is an integer or a decimal from 7 to 8; andL is an anti-EGFR antibody.
[0052] In addition, disclosed herein is an aqueous pharmaceutical composition for intravenous administration comprising:an antibody-drug conjugate represented by:13IPTS / 200429160.1Atty. Docket No. SMO-005WOor pharmaceutically acceptable salt thereof, wherein n is an integer or a decimal from 7 to 8, and L is an anti-EGFR antibody; anda pharmaceutically acceptable excipient.
[0053] For example, disclosed herein is an aqueous pharmaceutical composition for intravenous administration comprising:about 10 mg / mL of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein n is an integer or a decimal from 7 to 8, and L is an anti-EGFR antibody.about 20 mM histidine;about 8% sucrose (w / v); andabout 0.02% polysorbate 80 (w / v);wherein the pH of the composition is about 5.5 at room temperature.
[0054] Further disclosed herein, for example, is a method of treating a patient having advanced or metastatic solid cancer tumors selected from the group consisting of non-small cell14IPTS / 200429160.1Atty. Docket No. SMO-005WOlung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer, and in need thereof, comprising intravenously administering to the patient, once every two weeks or once every three weeks, an aqueous pharmaceutical composition formulated for intravenous administration comprising:about 10 mg / mL of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein n is an integer or a decimal from 7 to 8, and L is an anti-EGFR antibody;about 20 mM histidine;about 8% sucrose (w / v); andabout 0.02% polysorbate 80 (w / v);wherein the pH of the composition is about 5.5 at room temperature.
[0055] In some embodiments, a method disclosed herein comprises administering about1 mg / kg, about 2 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, or about 8 mg / kg of the antibody-drug conjugate to the patient.
[0056] Also disclosed herein is a method of treating a patient having advanced or metastatic solid cancer tumors, and in need thereof, comprising intravenously administering to the patient an effective amount of a pharmaceutical composition disclosed herein. In some embodiments, the advanced or metastatic solid cancer tumors is selected from the group consisting of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer.15IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0057] In some embodiments, a method disclosed herein comprises administering the pharmaceutical composition to the patient once every two weeks. In other embodiments, a method disclosed herein comprises administering the pharmaceutical composition to the patient once every three weeks. In certain embodiments, a method disclosed herein comprises administering about 1 mg / kg, about 2 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, or about 8 mg / kg of the antibody-drug conjugate to the patient.
[0058] In certain embodiments, the patient is a human. Parenteral administration may include subcutaneous injections, intravenous or intramuscular injections or infusion techniques. In certain embodiments, administering a disclosed antibody-drug conjugate or pharmaceutical composition may comprise intravenous administration. Disclosed methods of treatment may include administering a disclosed antibody-drug conjugate or pharmaceutical composition, for example, once daily, once weekly, once every two weeks, once every three weeks, once every four weeks, twice weekly, every other week; twice monthly; once a month; every other month; or even less often. In some embodiments, disclosed methods of treatment may include administering a disclosed antibody-drug conjugate or pharmaceutical composition, for example, on day 1 and on day 8 of a 21-day regimen cycle For example, disclosed methods of treatment may include administering a disclosed antibody-drug conjugate or pharmaceutical composition in a three- week (e.g., 21-day) regimen cycle comprising two consecutive weeks wherein the antibody-drug conjugate or pharmaceutical composition is administered to the patient on the first day of the week (e.g., on day 1 and on day 8), and one week wherein the antibody-drug conjugate or pharmaceutical composition is not administered to the patient.
[0059] By way of example only, the dose of the antibody-drug conjugate described herein for methods of treating a disease as described herein is, for example, about 0.5 mg / kg body weight of the patient, about 1.0 mg / kg body weight of the patient, about 1.5 mg / kg body weight of the patient, about 2.0 mg / kg body weight of the patient, about 2.5 mg / kg body weight of the patient, about 3.0 mg / kg body weight of the patient, about 3.5 mg / kg body weight of the patient, about 4.0 mg / kg body weight of the patient, about 4.5 mg / kg body weight of the patient, about 5.0 mg / kg body weight of the patient, about 5.5 mg / kg body weight of the patient, about 6.0 mg / kg body weight of the patient, about 6.5 mg / kg body weight of the patient, about 7.0 mg / kg body weight of the patient, about 7.5 mg / kg body weight of the patient, about 8.0 mg / kg16IPTS / 200429160.1Atty. Docket No. SMO-005WObody weight of the patient, about 8.5 mg / kg body weight of the patient, about 9.0 mg / kg body weight of the patient, 9.5 mg / kg body weight of the patient, about 10.0 mg / kg body weight of the patient, about 10.5 mg / kg body weight of the patient, about 11.0 mg / kg body weight of the patient, about 11.5 mg / kg body weight of the patient, or about 12.0 mg / kg body weight of the patient. In some embodiments, the dose of the antibody-drug conjugate described herein for methods of treating a disease as described herein is, for example, about 1.0 mg / kg body weight of the patient, about 1.5 mg / kg body weight of the patient, about 2.0 mg / kg body weight of the patient, about 2.5 mg / kg body weight of the patient, about 3.0 mg / kg body weight of the patient, about 3.5 mg / kg body weight of the patient, about 4.0 mg / kg body weight of the patient, about 4.5 mg / kg body weight of the patient, about 5.0 mg / kg body weight of the patient, about 5.5 mg / kg body weight of the patient, about 6.0 mg / kg body weight of the patient, about 6.5 mg / kg body weight of the patient, about 7.0 mg / kg body weight of the patient, about 7.5 mg / kg body weight of the patient, or about 8.0 mg / kg body weight of the patient. In other embodiments, the dose of the antibody-drug conjugate described herein for methods of treating a disease as described herein is, for example, about 1.0 mg / kg body weight of the patient, about 2.0 mg / kg body weight of the patient, about 3.0 mg / kg body weight of the patient, about 4.0 mg / kg body weight of the patient, about 5.0 mg / kg body weight of the patient, about 6.0 mg / kg body weight of the patient, about 7.0 mg / kg body weight of the patient, or about 8.0 mg / kg body weight of the patient. In certain embodiments, the dose is about 1.0 mg / kg body weight of the patient. In further embodiments, the dose is about 2.0 mg / kg body weight of the patient. In additional embodiments, the dose is about 3.0 mg / kg body weight of the patient. In some embodiments, the dose is about 4.0 mg / kg body weight of the patient. In other embodiments, the dose is about 5.0 mg / kg body weight of the patient. In still other embodiments, the dose is about 6.0 mg / kg body weight of the patient. In further embodiments, the dose is about 7.0 mg / kg body weight of the patient. In certain embodiments, the dose is about 8.0 mg / kg body weight of the patient.
[0060] The compounds of the present disclosure may be administered to patients (animals and humans) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. It will be appreciated that the dose required for use in any particular application will vary from patient to patient, not only with the particular compound or composition selected, but also with the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the17IPTS / 200429160.1Atty. Docket No. SMO-005WOpatient, and other factors which those skilled in the art will recognize, with the appropriate dosage ultimately being at the discretion of the attendant physician.
[0061] Treatment can be continued for as long or as short a period as desired. A suitable treatment period can be, for example, at least about one week, at least about two weeks, at least about one month, at least about six months, at least about 1 year, or indefinitely. A treatment period can terminate when a desired result is achieved.
[0062] In certain embodiments, an antibody-drug conjugate described herein is administered as a pure chemical. In some embodiments, the antibody-drug conjugate described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration (e.g., intravenous administration) and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21stEd. Mack Pub. Co., Easton, PA (2005)). In certain embodiments, the antibody-drug conjugate provided herein is substantially pure, in that it contains less than about 5%, or less than about 1%. or less than about 0.1%, of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.
[0063] Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and / or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and / or overall survival, or a lessening of symptom severity). Optimal doses are generally determined using experimental models and / or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient. Pharmaceutical compositions of this disclosure suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non- 18IPTS / 200429160.1Atty. Docket No. SMO-005WOaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
[0064] In some embodiments, the variable L in an antibody-drug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 1, SEQ ID NO:4, and SEQ ID NO: 7, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 10, SEQ ID NO: 13, and SEQ ID NO:16, respectively. In other embodiments, the variable L in an antibody-drug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 2, SEQ ID NO:5, and SEQ ID NO: 8, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 11, SEQ ID NO: 14, and SEQ ID NO:17, respectively. In further embodiments, the variable L in an antibody-drug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 3, SEQ ID NO:6, and SEQ ID NO: 9, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2. and CDR-L3 sequences shown in SEQ ID NO: 12. SEQ ID NO: 15, and SEQ ID NO:18, respectively.
[0065] In some embodiments, the variable L in an antibody-drug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 19, SEQ ID NO: 23, and SEQ ID NO: 27, respectively; and a light chain variable region (VL) comprising CDR-Ll, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 31, SEQ ID NO: 35, and SEQ ID NO: 39, respectively. In other embodiments, the variable L in an antibody-drug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 20, SEQ ID NO: 24, and SEQ ID NO: 28, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 32, SEQ ID NO:19IPTS / 200429160.1Atty. Docket No. SMO-005WO36, and SEQ ID NO: 40, respectively. In further embodiments, the variable L in an antibodydrug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 29, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 33, SEQ ID NO: 37. and SEQ ID NO: 41, respectively. In additional embodiments, the variable L in an antibody-drug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 22, SEQ ID NO: 26, and SEQ ID NO: 30, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 34, SEQ ID NO: 38, and SEQ ID NO: 42, respectively.
[0066] In some embodiments, the variable L in an antibody-drug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 43, SEQ ID NO: 47, and SEQ ID NO: 51, respectively; and a light chain variable region (VL) comprising CDR-Ll, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 55, SEQ ID NO: 59, and SEQ ID NO: 63, respectively. In other embodiments, the variable L in an antibody-drug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 44, SEQ ID NO: 48, and SEQ ID NO: 52, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 56, SEQ ID NO: 60, and SEQ ID NO: 64, respectively. In further embodiments, the variable L in an antibodydrug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 45, SEQ ID NO: 49, and SEQ ID NO: 53, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 57, SEQ ID NO: 61, and SEQ ID NO: 65, respectively. In additional embodiments, the variable L in an antibody-drug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 46, SEQ ID NO: 50, and SEQ ID NO: 54, respectively; and a light chain20IPTS / 200429160.1Atty. Docket No. SMO-005WOvariable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 58, SEQ ID NO: 62, and SEQ ID NO: 66, respectively.
[0067] In some embodiments, the variable L in an antibody-drug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 67, SEQ ID NO: 70, and SEQ ID NO: 73, respectively; and a light chain variable region (VL) comprising CDR-Ll, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 76, SEQ ID NO: 79, and SEQ ID NO: 82, respectively. In other embodiments, the variable L in an antibody-drug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 68, SEQ ID NO: 71. and SEQ ID NO: 74, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 77, SEQ ID NO: 80, and SEQ ID NO: 83, respectively. In further embodiments, the variable L in an antibodydrug conjugate described herein is an anti-EGFR antibody comprising, for example, a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 69, SEQ ID NO: 72, and SEQ ID NO: 77, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 78, SEQ ID NO: 81, and SEQ ID NO: 84, respectively.
[0068] In other embodiments, the variable L in an antibody-drug conjugate described herein is selected from the group consisting of: an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 85, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 86 (e.g., Anti-EGFR IgGl 1); an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 87, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 88 (e.g., Anti-EGFR IgGl 2); an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 89, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 90 (e.g., Anti-EGFR IgGl 3): an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 91, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 92 (e.g., Anti-EGFR IgGl 4); an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence21IPTS / 200429160.1Atty. Docket No. SMO-005WOshown in SEQ ID NO: 93, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 94 (e.g., Anti-EGFR IgGl 5); and an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 95. and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 96 (e.g., 6).
[0069] The amino sequences identified as SEQ ID NO: 1 through SEQ ID NO: 84 are shown in Table 1.Table 1.22IPTS / 200429160.1Atty. Docket No. SMO-005WO23IPTS / 200429160.1Atty. Docket No. SMO-005WO24IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0070] For example, contemplated anti-EGFR antibodies of the present disclosure may be represented as follows.Anti-EGFR IgGl 1 heavy chain, SEQ ID NO: 85
[0071] QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN25IPTS / 200429160.1Atty. Docket No. SMO-005WOAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGAnti-EGFR IgGl 1 light chain, SEQ ID NO: 86
[0072] DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECAnti-EGFR IgGl 2 heavy chain, SEQ ID NO: 87
[0073] QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGAnti-EGFR IgGl 2 light chain, SEQ ID NO: 88
[0074] DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQITREVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECAnti-EGFR IgGl 3 heavy chain, SEQ ID NO: 89
[0075] QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYAGRYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS26IPTS / 200429160.1Atty. Docket No. SMO-005WOCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKAnti-EGFR IgGl 3 light chain, SEQ ID NO: 90DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECAnti-EGFR IgGl 4 heavy chain, SEQ ID NO: 91
[0076] QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPAnti-EGFR IgGl 4 light chain, SEQ ID NO: 92
[0077] DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECAnti-EGFR IgGl 5 heavy chain, SEQ ID NO: 93
[0078] QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS27IPTS / 200429160.1Atty. Docket No. SMO-005WOGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKAnti-EGFR IgGl 5 light chain, SEQ ID NO: 94
[0079] DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECAnti-EGFR IgGl 6 heavy chain (variant of anti-EGFR IgGl 5 heavy chain), SEQ ID NO: 95
[0080] QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLG VIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSEDTAIYYCARALTYYDYEFAY WGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGAnti-EGFR IgGl 6 light chain, variant, SEQ ID NO: 96DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFS GSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDE QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
[0081] In some embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 90% identical (e.g., about: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 85, and a light chain consisting of an amino acid sequence that is at least 90%28IPTS / 200429160.1Atty. Docket No. SMO-005WOidentical (e.g., about: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 86. In other embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 85, and a light chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 86. In further embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 98% or 99% identical) to SEQ ID NO: 85. and a light chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 95%, 98% or 99% identical) to SEQ ID NO: 86. In additional embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 85, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 86.
[0082] In other embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 90% identical (e.g., about: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%. 98% or 99% identical) to SEQ ID NO: 87, and a light chain consisting of an amino acid sequence that is at least 90% identical (e.g., about: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 88. In other embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 87, and a light chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 88. In further embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 98% or 99% identical) to SEQ ID NO: 87, and a light chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 95%, 98% or 99% identical) to SEQ ID NO: 88. In additional embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 87, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 88.29IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0083] In further embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 90% identical (e.g., about: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%. 98% or 99% identical) to SEQ ID NO: 89, and a light chain consisting of an amino acid sequence that is at least 90% identical (e.g., about: 90%, 91%, 92%, 93%. 94%, 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 90. In other embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 89, and a light chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 90. In further embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 98% or 99% identical) to SEQ ID NO: 89, and a light chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 95%, 98% or 99% identical) to SEQ ID NO: 90. In additional embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 89, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 90.
[0084] In additional embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 90% identical (e.g., about: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 91, and a light chain consisting of an amino acid sequence that is at least 90% identical (e.g., about: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 92. In other embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 91, and a light chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 92. In further embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 98% or 99% identical) to SEQ ID NO: 91, and a light chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 95%, 98% or 99% identical) to SEQ ID NO: 92. In additional embodiments, a contemplated30IPTS / 200429160.1Atty. Docket No. SMO-005WOanti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 91, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 92.
[0085] In certain embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 90% identical (e.g., about: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 93, and a light chain consisting of an amino acid sequence that is at least 90% identical (e.g., about: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%. 98% or 99% identical) to SEQ ID NO: 94. In other embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%. 98% or 99% identical) to SEQ ID NO: 93, and a light chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 94. In further embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 98% or 99% identical) to SEQ ID NO: 93, and a light chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 95%, 98% or 99% identical) to SEQ ID NO: 94. In additional embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 93, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 94.
[0086] In some embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 90% identical (e.g., about: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 95. and a light chain consisting of an amino acid sequence that is at least 90% identical (e.g., about: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 96. In other embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 95, and a light chain consisting of an amino acid sequence that is at least 95% identical (e.g., about: 95%, 96%, 97%, 98% or 99% identical) to SEQ ID NO: 96. In further embodiments, a contemplated anti-31IPTS / 200429160.1Atty. Docket No. SMO-005WOEGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 98% or 99% identical) to SEQ ID NO: 95, and a light chain consisting of an amino acid sequence that is at least 98% identical (e.g., about: 95%, 98% or 99% identical) to SEQ ID NO: 96. In additional embodiments, a contemplated anti-EGFR antibody of the present disclosure comprises a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 95, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 96.
[0087] In some embodiments, the variable “n” as used herein, for example in an antibody-drug conjugate disclosed herein, represents the average number of units of the druglinker conjugated per antibody molecule in the antibody drug conjugate. The "average number of units" is also referred to as a drug-to-antibody ratio (DAR). In some embodiments, n is an integer or a decimal from 7 to 8. In other embodiments, n is, for example, 7.0, or 7.1, or 7.2, or 7.3, or 7.4, or 7.5, or 7.6, or 7.7, or 7.8, or 7.9, or 8.0. In additional embodiments, n is an integer or decimal from 1 to 8. In some embodiments n is 1, or 2, or 3, or 4, or 5, or 6, or 7, or 8.EXAMPLES
[0088] The following examples are provided for illustrative purposes only and are not intended to limit the scope of the disclosure.Example 1: Synthesis of (lS,2S)-N-((lS,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-lH,12H-benzo[de]pyrano[3',4':6,7]indolizino[l,2-b]quinolin- 1 -yl)-2-(hydroxymethyl)cyclopropane- 1 -carboxamide (Compound 1 )
[0089] Methyl 2-(hydroxymethyl)cyclopropane-l -carboxylate (25 mg, 0.175 mmol) was dissolved in 1 mL of methanol, and 870 pL of IM NaOH (1 equiv.) were added. The mixture was stirred at room temperature for 5 h, thus, the solvents were evaporated and the crude product was lyophilized from water. To the obtained solid were added exatecan mesylate (46 mg,32IPTS / 200429160.1Atty. Docket No. SMO-005WO0.5 equiv., 0,874 mmol), DMTMM (48 mg, 1 equiv., 0.175 mmol), and 10 mL of a 4:1 DMF / water mixture. The mixture was stirred at room temperature for 30 min. Solvents were evaporated under reduced pressure to a final volume of approx. 2 mL. The crude reaction mixture was purified by reverse-phase flash chromatography, using a column containing 25 g of diol-modified Cl 8, and using a gradient of ACN in water (060% ACN in H2O). A second purification was performed using a semipreparative column loaded with diol-modified C 18 and using a gradient of ACN in water (080% ACN in H2O). Two isomers were separated during the semipreparative purification. The title compound was isolated as a white powder after lyophilization from water / dioxane. MS calc, for C29H29FN3O6: 534.20, found: 534.10, [M+H]+.!H NMR (400 MHz, DMSO-( / 6) 58.72 (d, J= 8.9 Hz, 1H), 7.77 (d, J= 10.9 Hz, 1H), 7.32 (s, 1H), 6.53 (s, 1H), 5.56 (m, 2H), 5.44 (s, 2H), 5.31 - 5.05 (m, 2H). 4.52 (dd, J = 6.1, 5.0 Hz, 1H), 3.45 (m 1H), 3.26 (m, 1H), 3.20 - 3.08 (m, 1H), 2.38 (m, 2H), 2.24 - 2.00 (m, 2H), 1.87 (m, 2H), 1.76 (s, 1H), 1.60 - 1.48 (m, 1H), 1.01 (m. 1H), 0.88 (t, J= 7.3 Hz, 3H), 0.75 (m, 1H).Example 2: Synthesis of Linker-Payload Compound 2intermediate 233IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0090] Intermediate 1. FmocGGFG-OAc (1 equiv., 0.0892 mmol, 60 mg) was dissolved into 2 mL of DMF and (,2S)-2-(hydroxymethyl)cyclopropane-l-carboxylic acid (2 equiv., 0.1784 mmol, 21 mg) was added, followed by 10 pL of a 4M HC1 solution in dioxane. The reaction mixture was stirred at room temperature for 1 h, to be then directly loaded on column for purification. Purification was performed by reverse-phase flash chromatography (25 g, diol-modified C18, 0100% ACN / H2O). Fractions containing the product were lyophilised from water (43 mg, 70 %). MS calc, for C36H40N5O9: 686.28, found: 686.34, [M+H]+.
[0091] Intermediate 2. To a solution of the previously prepared intermediate 1 (43 mg, 0.0628 mmol) in DMF (2 mL) were added exatecan mesylate (1.1 equiv., 0.0691 mmol, 37 mg), DMTMM (1.2 equiv., 0.0754 mmol, 21 mg), DIPEA (20 pL) and water (400 pL). The reaction mixture was stirred at room temperature for 1 h, to be then directly loaded on column for purification. Purification was performed by reverse-phase flash chromatography (25 g, diol-modified C18, 0100% ACN / 0 / 1% TFA). Fractions containing the product were lyophilised from water (41 mg, 59 %). MS calc, for C60H60FN8O12: 1103.43, found: 1103.40, [M+H]+.
[0092] Intermediate 3. The previously prepared intermediate 2 (41 mg, 0.0372 mmol) was dissolved in DMF (2mL) and morpholine (100 pL) was added. The reaction mixture was stirred at room temperature for 1 h. Purification was performed by reverse-phase HPLC chromatography (semipreparative, diol-modified C18, 0 - 100% ACN / 0.1% TFA). Fractions containing the product were lyophilised from water (14 mg, 44%). MS calc, for C45H50FN8O10: 881.36, found: 881.65, [M+H]+.34IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0093] Compound 2. The previously prepared intermediate 3 (14 mg, 0.0160 mmol) was dissolved in 2 mL of anhydrous DMF. 2,5-dioxopyrrolidin-l-yl 3-(2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)ethoxy)propanoate (1.1 equiv., 0.0175 mmol. 5.4 mg) and DIPEA (2.5 pL) were added and the reaction mixture was stirred at room temperature for 1 h. Purification was performed by reverse-phase HPLC chromatography (semipreparative, diol-modified C18, 0100% ACN / 0.1% TFA). Fractions containing the product were lyophilised from water (7 mg, 41 %). MS calc, for C54H59FN9O14: 1076.42, found: 1076.42, [M+H]+. ’H NMR (500 MHz, DMSO-t / 6) 58.73 (t, J= 9.3 Hz, 1H), 8.42 (t, J= 6.6 Hz, 1H), 8.25 (t, J= 5.8 Hz, 1H), 8.10 (q, J = 7.5, 6.4 Hz, 2H), 7.99 (q, J = 6.7, 5.8 Hz, 1H), 7.79 (d, 7= 10.8 Hz, 1H), 7.31 (s, 1H), 7.29- 7.19 (m, 4H), 7.19 -7.12 (m, 1H), 7.00 (s, 2H), 6.51 (s, 1H), 5.56 (m, 1H), 5.49 -5.38 (m, 2H),5.19 (s, 2H), 5.16 (d, J= 4.7 Hz, 1H), 4.56 (d. J= 6.7 Hz, 1H), 4.52 (d, J= 6.7 Hz, 1H). 4.48 (m.1H), 3.78 - 3.69 (m, 2H), 3.67 (d, J = 5.7 Hz, 2H), 3.57 (d, J= 5.8 Hz, 3H), 3.53 (t, 7 = 6.6 Hz, 2H), 3.46 (t, 7= 5.8 Hz, 3H), 3.26 (m, 1H), 3.14 (m, 1H), 3.02 (m, 1H), 2.80 - 2.75 (m, 1H), 2.39 (d. 7 = 3.9 Hz, 3H), 2.32 (t, 7 = 6.5 Hz. 2H), 2.14 (m, 2H), 1.86 (m, 2H), 1.61 - 1.49 (m. 2H), 1.03 (m, 1H), 0.88 (t, 7 = 7.3 Hz, 3H), 0.77 (p, 7 = 4.1 Hz, 1H).Example 3: General Procedure for the Synthesis of Antibody Drug Conjugates
[0094] Anti-EGFR antibody-drug conjugates were prepared by reacting Compound 2 with an anti-EGFR antibody described herein and forming a thioether bond at cysteine residues forming disulfide bond sites present between light and heavy chain antibody subunits and heavy and heavy chain antibody subunits respectively.
[0095] For example. 2.4 to 10 mg / ml of respective anti-EGFR IgGl monoclonal antibody 1, 2, 3, 4, or 5 in lx PBS pH 7.4, 10% sucrose, 5 mM EDTA, was partially reduced by adding 40 molar equivalents of TCEP (ThermoFisher) relative to monoclonal antibody for 60 min at 20 °C. Compound 2 as a lyophilized powder was dissolved in 100% DMSO (weight per volume) and added to the reduced antibody reaction mixture at 2-37 molar equivalents relative to monoclonal antibody as 5-8 % v / v solution of DMSO, and the reaction solution was nutated for 2 hr at 20 °C. Afterwards, N-acetylcysteine (SigmaAldrich) was added at 1 molar equivalent relative to Compound 2, and the reaction mixture incubated for 20 min at 20 °C. Excess quenched linker-drug was separated from respective antibody-drug conjugates by cationexchange chromatography (Cytiva, HiTrap SP HP resin), composition of buffer A was 10%35IPTS / 200429160.1Atty. Docket No. SMO-005WOsucrose, 12.5 mM sodium acetate pH 5.0, 20 mM NaCl, and buffer B was 10% sucrose, 12.5 mM sodium acetate pH 5.0, IM NaCl. Antibody drug conjugate and unconjugated linker-drug mixture in lx PBS pH 7.4 were diluted in 10% sucrose, 12.5 mM Na-acetate pH 5.0, 0 mM NaCl buffer and loaded onto HiTrap SP HP resin column (Cytiva). Respective non-conjugated linkerdrugs did not bind to the column, while respective antibody-drug conjugates bound to the column and were eluted in 10% sucrose. 100-150 mM NaCl, 12.5 mM Na-acetate pH 5.0 buffer. Analytical size-exclusion chromatography (Cytiva, Superdex 200 10 / 300 in lx PBS, pH 7.4 buffer or Agilent AdvanceBio SEC 300A, 4.6 x 150mm, 2.7 micron particle-size column, in lx PBS pH 7.4, 10% isopropanol buffer) showed that antibody drug conjugates were >90 % monomeric. Drug-linker to antibody ratio of antibody drug conjugates was determined using reverse phase liquid chromatography mass spectrometry (RPLC-MS) of antibody’s heavy and light chain subunit species using the approach known in the art (Zhu X. et al. 2020. J Pharm Anal. 10(3): 209-220; Firth D. et al. 2015 Analytical Biochemistry, 485, 34-42).Example 4: Synthesis of Antibody Drug Conjugate Compound 3
[0096] Antibody drug conjugate compound 3 was prepared according to general procedure in Example 3 using 20 molar equivalents of linker payload compound 2 to anti-EGFR IgGl monoclonal antibody 1. DAR based on RPLC-MS was 7.1.Example 5: Synthesis of Antibody Drug Conjugate Compound 4
[0097] Antibody drug conjugate compound 4 was prepared according to general procedure in Example 3 using 30 molar equivalents of linker payload of compound 2 to anti-EGFR IgGl monoclonal antibody 3. DAR based on RP-HPLC was 7.8.Example 6: Synthesis of Antibody Drug Conjugate Compound 5
[0098] Antibody drug conjugate compound 5 was prepared according to general procedure in Example 3 using 30 molar equivalents of linker payload of compound 2 to anti-EGFR IgGl monoclonal antibody 4. DAR based on RP-HPLC was 7.9.Example 7: Synthesis of Antibody Drug Conjugate Compound 636IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0099] Antibody drug conjugate compound 6 was prepared according to general procedure in Example 3 using 34 molar equivalents of linker payload of compound 2 to anti-EGFR IgGl monoclonal antibody 5. DAR based on RP-HPLC was 7.6.Example 8: Study Description
[0100] A Phase 1, first in human, open-label multicenter study to evaluate Compound 5, an antibody drug conjugate targeting EGFR in participants with advanced or metastatic select solid tumors, is conducted. The study investigates previously treated advanced or metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC) and colorectal cancer (CRC).
[0101] Phase la Primary Objectives: To evaluate the safety and tolerability of Compound 5 as a single agent in previously treated participants with known epidermal growth factor receptor (EGFR)-expressing select advanced or metastatic solid tumors; To determine the maximum tolerated dose (MTD) at every 3 weeks (Q3W) and every 2 weeks (Q2W) and the recommended doses for expansion (RDEs) of Compound 5 as a single agent in previously treated participants with known EGFR-exp res sing select advanced or metastatic solid tumors.
[0102] Phase la Secondary Objectives: To characterize the single and multiple-dose pharmacokinetic (PK) profiles of Compound 5 total antibody, total antibody drug conjugate (ADC), and Topoisomerase I (TOPI) inhibitor payload; To evaluate the immunogenicity of Compound 5; To evaluate the preliminary anti-tumor activity of Compound 5 in previously treated participants with known EGFR-expressing select advanced or metastatic solid tumors.
[0103] Phase la Exploratory Objectives: To explore the pharmacodynamic (PD) effects of Compound 5 and their association with PK, safety, and efficacy endpoints; To assess disease-related, molecular, and cellular biomarkers in the circulation and in tumor tissue and their relationship with clinical endpoints.
[0104] Phase lb Primary Objective: To further evaluate the preliminary response of Compound 5 as a single agent in previously treated participants with known EGFR-expressing select advanced or metastatic solid tumors.37IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0105] Phase lb Secondary Objectives: To further evaluate the preliminary additional anti-tumor activity of Compound 5 as a single agent in previously treated participants with known EGFR-expressing select advanced or metastatic solid tumors; To further assess the overall safety and tolerability of Compound 5; To further characterize the PK profiles of Compound 5; To further evaluate the immunogenicity of Compound 5.
[0106] Phase lb Exploratory Objectives: To further assess disease-related, molecular, and cellular biomarkers in the circulation and in tumor tissue and their relationship with clinical endpoints.
[0107] Phase la Primary Endpoints: Number and proportion of participants who experience dose-limiting toxicities (DLTs) as defined in the protocol; Adverse Events (AEs) as characterized by type, frequency, severity (as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 [NCI CTCAE v5.0]), timing, seriousness, and relationship to study drug in order to establish the RDE(s); Laboratory abnormalities as characterized by type, frequency, severity and timing.
[0108] Phase la Secondary Endpoints: PK parameters of Compound 5 including, but not limited to maximum concentration (Cmax), time to maximum concentration (Tmax), area under the concentration-time curve (AUC), clearance (CL) and terminal elimination half-life (ti / 2) as data permit; Presence of human plasma anti-drug antibodies (ADAs) (anti-Compound 5 antibodies); Objective Response Rate (ORR) per investigator assessment using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); Disease control rate (DCR), best overall response (BOR), duration of response (DoR). progression-free survival (PFS). and overall survival (OS).
[0109] Phase la Exploratory Endpoints: Tumor markers, including but not limited to EGFR expression, from tumor biopsy tissue and circulating tumor DNA; Exploratory molecular analysis in peripheral blood samples for the effects of EGFR inhibition and TOPI activity.
[0110] Phase lb Primary Endpoint: Objective response rate per investigator assessment.38IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0111] Phase lb Secondary Endpoints: Disease control rate, best overall response, duration of response, progression-free survival, and overall survival; adverse events as characterized by type, frequency, severity, timing, seriousness, and relationship to study drug; Laboratory abnormalities as characterized by type, frequency, severity and timing; pharmacokinetic concentrations and parameters of Compound 5; Presence of human plasma antidrug antibodies (anti-Compound 5 antibodies).
[0112] Phase lb Exploratory Endpoints: Blood and tumor samples may be obtained for exploratory molecular analysis including, but not limited to, immunohistochemistry (IHC) and exploratory molecular assays for intrinsic and acquired resistance markers against either the anti-EGFR portion or the TOPI inhibitor portion of Compound 5.
[0113] Number of Participants: Up to 90 adult participants in total are expected to be enrolled in Dose Finding (Phase la; n up to 40 for Dose Escalation and n up to 50 for Dose Exploration). Up to 80 participants may be enrolled in the Dose Expansion cohort (Phase lb). Participants with advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC) and colorectal cancer (CRC) who have progressed after standard therapy will be studied.Study Design:
[0114] This is a Phase 1, first-in-human, open-label study to evaluate the safety, tolerability, and preliminary efficacy of Compound 5 in participants with select advanced or metastatic solid tumors that are known to express EGFR. The study consists of Phase la Dose Finding (Dose Escalation and Dose Exploration; n up to 90) and Phase lb (Dose Expansion; n up to 80).
[0115] Phase la Dose Finding consists of Dose Escalation in previously treated participants with select EGFR expressing advanced or metastatic solid tumor types, followed by Dose Exploration, consisting of cohorts of up to 15 participants at a specific dose and schedule to identify the optimal dose and schedule or the top two dose(s) and schedule(s) to take into Phase lb. The maximum number of participants for Dose Exploration is 50. Tumor types for Dose Exploration cohorts either include all the tumor types from Dose Escalation or a subset of these tumors based on the safety and efficacy observed by tumor type in Dose Escalation.39IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0116] Phase lb Dose Expansion further characterizes the safety, efficacy, and optimal dose of Compound 5 in one or two tumor types included in Dose Escalation and Exploration. The tumor types are selected based on a comprehensive review of the efficacy, safety, and PK from Dose Escalation and exploration. For each tumor type selected for Dose Expansion, either one or two dose(s) and schedule(s) are tested. Up to 20 participants are treated at any given dose and schedule per tumor type. The maximum sample size for Phase lb Dose Expansion is 80 participants.Phase la: Dose Finding:Dose Finding - Dose Escalation:
[0117] The study initiates with a Dose Escalation portion assessing Q3W dosing schedule (with a 21 -day cycle) and subsequent Q2W dosing schedule (with a 28-day cycle) in participants with select advanced or metastatic solid tumors. Up to 40 participants may be enrolled in the Dose Escalation cohorts at Q3W and Q2W. Dose levels are outlined in Table 2.Table 2. Indicated Dose Levels for Q3W and Q2WDose Finding - Dose Exploration:40IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0118] Dose Exploration identifies the optimal dose(s) and / or schedule(s) to take into the Phase lb Dose Expansion portion of the study. The maximum number of participants for Dose Exploration is 50, and the maximum Dose Exploration cohort size for a given dose and schedule is 15. Tumor types for Dose Exploration either include all the tumor types from Dose Escalation or a subset of these tumors based on the safety and efficacy observed by tumor type in Dose Escalation. Neither pre-screening nor confirmatory testing for EGFR positivity are required to be eligible as EGFR testing and is performed retrospectively. Participants are enrolled to all other inclusion and exclusion criteria as those participants enrolled into the Dose Finding portion of the study. Participants in Dose Exploration are assigned to the dose levels and / or schedules chosen for Dose Exploration. Safety, efficacy, PK, PD and immunogenicity data are collected. At the end of Dose Exploration, optimal RDE(s) of Compound 5 to be used for the Phase lb expansion are determined.Phase lb: Dose Expansion:
[0119] Phase lb Dose Expansion further characterizes the safety, efficacy, and optimal dose of Compound 5 in one or two tumor types which were included in Dose Escalation and Exploration. The tumor types are selected based on a comprehensive review of the efficacy, safety, and PK from Dose Escalation and Exploration. For each tumor type selected for Dose Expansion, either one or two dose(s) and schedule(s) are tested. Up to 20 participants are treated at any given dose and schedule per tumor type. The maximum sample size for Phase lb Dose Expansion is 80 participants. For each selected tumor, if two doses or schedules are selected, participants in Dose Expansion are randomized to the two groups. Safety, efficacy, PK, PD and immunogenicity data are collected.Inclusion Criteria:
[0120] 1) Participants with locally advanced, recurrent or metastatic disease; locally advanced or recurrent disease must not be amenable to resection with curative intent. 2) Participants with the following histologically confirmed tumor types for: a) Dose Escalation: HNSCC, NSCLC, ESCC, CRC (left-sided), b) Dose Exploration: All or a subset of tumors tested in Dose Escalation, c) Dose Expansion: Subset of tumors tested in Dose Escalation. 3) Participants must meet the following criteria for specific tumor types: a) HNSCC should have41IPTS / 200429160.1Atty. Docket No. SMO-005WOeligible primary tumor locations in the oropharynx, oral cavity, hypopharynx, and larynx.Participants with a primary tumor location in the oropharynx must have available results from testing HPV (p16 IHC) status. Participants with a primary tumor site of nasopharynx (any histology) or unknown primary squamous cell carcinoma (including p16+ unknown primary) will not be eligible to participate; b) NSCLC: Participants with advanced incurable or metastatic NSCLC histologically confirmed to be of any non-small cell histology without a small cell or neuroendocrine component. Participants are required to have undergone testing for genomic alterations per local standard of care, including but not limited to EGFR / ALK / ROS1 / BRAF; c) ESCC: Participants with histologically confirmed unresectable locally advanced, recurrent, or metastatic squamous cell carcinoma of the esophagus. Participants are required to have undergone testing for genomic / molecular alterations per local standard of care; d) CRC:Participants with histologically confirmed left- sided mCRC. Participants are required to have undergone testing for genomic alterations per local standard of care. 4) Participants must meet the following criteria with regard to prior treatment: a) Dose Escalation: Participants who have relapsed or progressed following prior anticancer therapy in the advanced / metastatic setting and for whom no approved or standard therapy is available; b) Dose Exploration and Dose Expansion: Participants must meet the following tumor-specific criteria: I. HNSCC: Received platinum-based chemotherapy and checkpoint inhibitors (CPI) (in combination or sequential), and have received no more than 3 prior lines of therapy in the advanced or metastatic setting; II. NSCLC: i. For participants with a targetable molecular alteration: Received appropriate standard targeted therapy and no more than 2 prior lines of systemic chemotherapy in the advanced / metastatic setting; ii. For participants without a targetable molecular alteration:Received platinum-based chemotherapy and CPI (in combination or separately), and have received no more than 2 prior lines of systemic chemotherapy in the advanced / metastatic setting; III. ESCC: Received platinum-based chemotherapy, appropriate standard targeted therapy for an applicable molecular tumor alteration and have received no more than 3 prior lines of therapy in the advanced / metastatic setting; IV. CRC: i. For participants with a targetable molecular alteration (including dMMR or MSI-H): Received appropriate standard therapy for the alteration, at least 2 prior lines of systemic chemotherapy, and no more than 4 prior lines of therapy in the advanced / metastatic setting; ii. For participants without a targetable molecule alteration:Received at least 2 prior lines of systemic chemotherapy (including an oxaliplatin-based42IPTS / 200429160.1Atty. Docket No. SMO-005WOchemotherapy), VEGF-based therapy, and no more than 4 prior lines of therapy in the advanced / metastatic setting. 5) Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1. 6) Participants must have measurable disease according to RECIST v1.1. Lesions in a prior radiation field must have progressed subsequent to radiotherapy to be considered measurable. 7) An archived tumor tissue from the most recent biopsy (formalin-fixed paraffin-embedded [FFPE] sample collected within 2 years) will be required prior to study entry. When possible or if feasible, tissue samples should preferably be taken after the most recent therapy. Fine needle aspirates or samples from bone lesions are not acceptable. If archival tissue is not available, a fresh biopsy sample will be required prior to study entry. 8) Adequate bone marrow function as demonstrated by the following laboratory values and as appropriate for the disease under study: a) Absolute Neutrophil Count >1,500 / mm3 (>1.5 x 109 / L); b) Platelets >100,000 / mm3 (>100 x 109 / L) without transfusion within 2 weeks of C1D1; c) Hemoglobin >9 g / dL (>90 g / L) without transfusion within 2 weeks of C1D1; d) Adequate renal function (estimated creatinine clearance or glomerular filtration rate >60 mL / min as calculated using the Cockroft-Gault equation. 9) Adequate organ function as demonstrated by the following laboratory values and as appropriate for the disease under study: a) Total serum bilirubin <1.5 x upper limit of normal (ULN) (note: participants with elevated bilirubin with documented Gilbert’s syndrome will not be eligible); b) Aspartate transaminase (AST) and alanine transaminase (ALT) <3.0 x ULN; c) Alkaline phosphatase <3.0 x ULN; d) Serum albumin >3 g / dL; e) Prothrombin time (PT) and partial thromboplastin time (PTT) <1.5 x ULN; f) International normalized ratio (INR) <1.5 without anticoagulants, INR <3 if on prophylactic anticoagulation therapy. 10) Serum pregnancy test (for females of childbearing potential) negative at screening. 11) Male and female participants of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 6 months after the last dose of Compound 5. A participant is of childbearing potential if. in the opinion of the Investigator, he / she is biologically capable of having children and is sexually active. 12) Participant has recovered to Grade <1 per NCI CTCAE v5.0 from toxic effects of prior therapy (systemic and radiation), and / or complications from prior surgical intervention before starting study drug except for AEs not deemed reversible, which do not constitute a safety risk by Investigator judgement upon review by the Medical Monitor. Note: Stable chronic conditions (Grade <2) that are not expected to resolve (e.g., neuropathy, myalgia, alopecia, and prior43IPTS / 200429160.1Atty. Docket No. SMO-005WOtherapy-related endocrinopathies) are exceptions. 13) Participants who are willing and able to comply with scheduled visits, treatment plans, laboratory, tests and other procedures.Exclusion Criteria:
[0121] 1) Participants with disease suitable for local therapy with curative intent. 2) Has a life expectancy of less than 3 months and / or has rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator. 3) Prior treatment with any ADCs that have an active TOPI inhibitor-based component. 4) Participants receiving systemic anti-cancer therapy within 28 days or 5 half-lives (whichever is shorter) of CID 1 (hormonal therapy for prostate and breast cancer, and therapy for bone metastases or cancer-related hypercalcemia is permitted). 5) Participants who received greater than 30 Gy of radiation dose to the lung within 3 months of CID 1 or any radiation therapy to the chest within 4 weeks. Participants who received palliative radiation therapy to other areas (i.e., bone, limited field or less than 10 fractions of therapy) greater than 2 weeks or more to non-central nervous system (CNS) and brain disease and recovered from all radiation-related toxicities. did not require corticosteroids, without evidence of radiation pneumonitis by CID 1 will be included in the study. 6) Any medical condition requiring systemic corticosteroids (dosed >10 mg / day oral prednisone or equivalent), or any other immunosuppressive therapy within 14 days prior to the first dose of study drug. Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study. 7) Participants with a known history of or current non-infectious pneumonitis / interstitial lung disease (ILD) requiring steroid treatment, or for whom suspected pneumonitis / ILD cannot be ruled out by imaging at screening or clinically severe pulmonary compromise due to intercurrent pulmonary illness and / or pulmonary disorder (e.g., severe chronic obstructive pulmonary disease, restrictive lung disease, etc.) requiring supplemental oxygen or any prior pneumonectomy. 8) Any experimental antibodies or live vaccines within 28 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella / zoster, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. 9) Known symptomatic CNS metastases or leptomeningeal disease requiring steroids. Participants with44IPTS / 200429160.1Atty. Docket No. SMO-005WOpreviously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for these metastases and are clinically stable off anticonvulsants for at least 4 weeks and are neurologically stable before enrollment. No evidence of progression for at least 4 weeks confirmed by imaging during study screening. 10) Active known second malignancy with the exception of any of the following: a) Adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer; b) Adequately treated Stage I cancer from which the participant is currently in remission and has been in remission for >2 years; c) Any other cancer from which the participant had been disease free from >3 years. 11) Participants with intolerance to or who have had a severe allergic or anaphylactic reaction to antibodies or infused therapeutic proteins or to any of the biopharmaceutics produced in CHO cells, or participants who have had a severe allergic or anaphylactic reaction or severe infusion reaction to any of the substances included in the Compound 5 drug formulation (e.g., polysorbate 80). 12) Has an active, uncontrolled, clinically significant bacterial, fungal, or viral infection, or any ongoing infection requiring systemic therapy. 13) Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1 / 2 antibodies) or acquired immune deficiency syndrome (AIDS) related illness. 14) Has a diagnosis of immunodeficiency (with the exception of hypogammaglobulinemia) or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. 15) Has a known active or known prior history of Hepatitis B (HBV) infection (e.g., Hepatitis B surface antigen [HBsAg] reactive or detectable quantitative levels of HBV DNA) or known active Hepatitis C (HCV) (e.g., HCV RNA [qualitative] is detected). 16) Any of the following within 6 months of the first dose of study drug: myocardial infarction, severe / unstable angina, coronary / peripheral artery bypass graft, New York Heart Association (NYHA) Class II or greater congestive heart failure, uncontrolled hypertension (defined as systolic blood pressure >160 mmHg or diastolic >100 mmHg for greater than 4 weeks despite optimal medical management), cerebrovascular accident, transient ischemic attack, deep venous thrombosis (except for thrombi considered device- associated and not clinically significant), arterial thrombosis, symptomatic pulmonary embolism, or any other significant thromboembolism. 17) History of clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes. second- or third-degree atrioventricular heart block without a permanent pacemaker in place)45IPTS / 200429160.1Atty. Docket No. SMO-005WOand / or serious cardiac arrhythmias requiring anti-arrhythmic medication. 18) QT interval corrected for heart rate Frederica's formula (QTcF) >480 msec (based upon value from triplicate ECGs). 19) Participants with an active autoimmune disease that has required systemic treatment within 12 months of C1D1 (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. 20) History of chronic malabsorption, symptomatic chronic enteropathy or ongoing diarrheal disease of any etiology causing Grade >2 diarrhea despite optimal medical management. 21) Any major surgery, non-healing wound, ulcer, or bone fracture requiring hospitalization within 2 months prior to the first dose of study drug. 22) History of bone marrow transplant or solid organ transplant. 23) Any major surgery or significant traumatic injury within 28 days prior to enrollment. Placement of a central venous access catheter is not considered a major surgical procedure and is therefore permitted. For minor surgeries and procedures such as a tumor biopsy, placement of vascular access device, or interventional radiology procedure, it is acceptable to have had the procedure within 7 days or more of study drug. 24) History of symptomatic uncontrolled ascites, pleural effusion or pericardial effusion requiring therapeutic intervention within 1 month prior to the first dose of study drug. Note exception: participants with stable effusions managed with indwelling pleural catheters may be eligible upon review by the Medical Monitor. 25) Participants who are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial. 26) Is currently participating or has participated in a study of an investigational agent or investigational device within 4 weeks prior to the first dose of study drug. 27) Other medical or psychiatric condition, including uncontrolled systemic infection, recent (within the past year) or active suicidal ideation or behavior, geographic condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator or Sponsor, would make the participant inappropriate for entry into this studyDosage Form and Administration:
[0122] Compound 5 for injection (drug product) is a sterile frozen liquid drug product, contained in a single-use 20 mL glass vial with 20 mm flip-off seal over 20 mm rubber stopper46IPTS / 200429160.1Atty. Docket No. SMO-005WOstored at < -60 °C. The formulation contains 10 mg / mL Compound 5, 20 mM histidine, 8% sucrose (w / v), 0.02% polysorbate 80 (w / v), pH 5.5. Compound 5 is administered via intravenous (IV) infusion and must be thawed at room temperature prior to preparation and administration. Doses are infused over approximately 60-90 minutes on an outpatient basis. The use of an infusion pump is the preferred method of administration to ensure accurate delivery of the study drug; gravity drips are allowed. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no study drug delays, a cycle will be 21 days for Q3W dosing and 28 days for Q2W dosing.Example 9: In Vivo Pharmacology: Anti-Tumor Activity of Compound 5 in EGFR-Expressing Tumor Cell Line-Derived Xenograft Models
[0123] In vivo pharmacology of Compound 5 was evaluated as a single agent in mouse xenograft models from multiple indications and having a range of EGFR expression. Robust anti-tumor activity was observed following a single dose administration of Compound 5, leading to significant tumor growth inhibition and tumor eradication in multiple tumor models, including wild-type and mutated EGFR, KRAS and BRAF mutant models.
[0124] For example, the efficacy of an ADC is dependent on cell surface expression level of the target on tumor cells. The efficacy of Compound 5 was evaluated in three EGFR-expressing human tumor cell line-derived xenograft models from different tumor indications: MDA-MB-468 (EGFR-high, triple negative breast cancer, FIG. 1), FaDu (EGFR-mid, nasopharyngeal cancer, FIG. 2) and CFPAC-1 (EGFR-low, pancreatic ductal adenocarcinoma, FIG. 3). The results are shown in FIG. 1 ((EGFR-high, triple negative breast cancer), FIG. 2 (EGFR-mid, nasopharyngeal cancer), and FIG. 3 (EGFR-low, pancreatic ductal adenocarcinoma). Tumor volume (mm3) of single intravenous dose of Compound 5 at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was monitored until between day 22-29 post dose. Data represented as mean ± SEM, n=12 / each data point. As shown in FIG. 1, FIG. 2, and FIG. 3, single administration of Compound 5 exerted strong anti-tumor activity in all models.Example 10: In Vivo Pharmacology: Anti-Tumor Activity of Compound 5 in EGFR Mutated Cell Line-Derived Xenograft Models47IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0125] Mutations in EGFR are the most prominent resistance mechanisms to EGFR targeting agents in the clinic, which limits treatment options for such patients to, for example, anti-EGFR monoclonal antibody therapies, tyrosine kinase inhibitor (TKI) therapies, chemotherapy and radiation therapy. Small in-frame deletions in exon 19 and L858R in exon 21 of the EGFR gene together comprise 80% to 90% of all EGFR mutations and are shown to confer tyrosine kinase inhibitor (TKI) sensitivity in vitro. In contrast, the T790M mutation produces a drug-resistant variant of the targeted kinase and is present in about half of the lung cancer patients with acquired resistance. EGFR targeting ADCs that can inhibit growth of EGFR mutant tumors by exhibiting cytotoxic activity, offers great potential as treatment option to bypass these intracellular resistance mechanisms.
[0126] The effect of Compound 5 on tumor growth inhibition was therefore evaluated in two mutated EGFR-expressing non-small cell lung cancer cell line-derived xenograft models, HCC827 harboring the exon 19 deletion, and NCI-H1975, having an EGFR L858R / T790M double mutation. The results for HCC827 are shown in FIG. 4, where percent (%) tumor growth inhibition of single intravenous dose of Compound 5 at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was measured at day 28 post dose. Data represented as mean ± SEM, n=12 / each data point. P values are indicated as follows: * = P <0.05; *** = P <0.001; and **** = P <0.0001. The results for NCI-H1975 are shown in FIG. 5, where percent (%) tumor growth inhibition of Compound 5 treatment at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was measured at day 21 post dose. Data represented was mean ± SEM, n=12 / each data point. P values were indicated as follows: **** = P <0.0001. As shown in FIG. 4 and FIG. 5, Compound 5 showed strong anti-tumor efficacy in both mutated EGFR-expressing non-small cell lung cancer cell line-derived xenograft model, demonstrating its efficacy against EGFR-mutated cancers.Example 11: In Vivo Pharmacology: Anti-Tumor Activity of Compound 5 in KRAS and BRAF Mutated Cell Line-Derived Xenograft Models
[0127] KRAS and BRAF mutations are associated with poor response to EGFR-dependent TKI therapy due to constitutive downstream activation of the EGFR pathway. Almost 7% of human cancers are associated with mutations in BRAF, with most mutations being the somatic point mutation V600E in exon 15, while 20.4% of non-small cell lung cancer patients48IPTS / 200429160.1Atty. Docket No. SMO-005WOand 35.8% of colorectal patients carry KRAS mutations. The anti-tumor activity of Compound 5 was evaluated in two mutated cell line-derived xenograft models based on their mutational status: COLO205, a human colorectal adenocarcinoma BRAF V600E-mutant cell line; and HCT 116, a human colon cancer cell line which harbors a KRAS G13D mutation, both of which do not respond to cetuximab.
[0128] The results for COLO205 are shown in FIG. 6, where percent (%) tumor growth inhibition of treatment at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was measured at day 21 post dose. Data represented as mean ± was SEM, n=12 / each data point. P values are indicated as follows: ** = P <0.01; *** = P <0.001; **** = P <0.0001. As shown in FIG. 6, Compound 5 showed strong anti-tumor activity in the COLO205 model at 10, 3, and 1 mg / kg dose levels. The results for HCT 116 are shown in FIG. 7. where percent (%) tumor growth inhibition of Compound 5 treatment at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was measured at day 25 post dose. Data represented as mean ± SEM, n=12 / each data point. P values are indicated as follows: **** = P <0.0001. As shown in FIG. 7, Compound 5 showed strong anti-tumor activity at 10, 3, and 1 mg / kg dose levels following single or three doses. The results demonstrate the anti-tumor efficacy of Compound 5 in treating KRAS and BRAF mutated EGFR-expressing cancers which are resistant to cetuximab by a direct cytotoxic effect on the tumor cells.Example 12: In Vivo Pharmacology: Anti-tumor activity of Compound 5 in a Colorectal Cancer Patient Derived Organoid Xenograft Model
[0129] To address heterogeneity of primary tumors, the efficacy of Compound 5 was tested in a colorectal cancer patient-derived organoid model established from cryopreserved primary colorectal adenocarcinoma patient tumor cells and shown to have low expression levels of EGFR. The results are shown in FIG. 8, where percent (%) tumor growth inhibition of single dose and 3 doses of Compound 5 at the indicated dosage (1 mg / kg, 3 mg / kg, or 10 mg / kg) was measured at day 35 post first dose. Data was represented as mean ± SEM, n=12 / each data point. P values were: ** = P <0.005; **** = P <0.0001. As shown in FIG. 8, Compound 5 showed strong anti-tumor efficacy in a dose-dependent manner in the in vivo patient-derived organoid model following single or multiple dose treatments.49IPTS / 200429160.1Atty. Docket No. SMO-005WOExample 13: Tumor growth suppression effect on in vivo bystander model using human lung mucoepidermoid carcinoma cell line NCI-H292 co-inoculated with human colon adenocarcinoma cell line SW620-luc of anti-EGFR antibody drug conjugates Compound 3 and Compound 4
[0130] NCI-H292 human lung mucoepidermoid carcinoma cell line NCI-H292 was purchased from ATCC. SW620-luc (luciferase) cells was purchased from FenicsBIO. NOD-SCID mice (Charles River Labs, strain code #394), female, 6-8 weeks old were inoculated subcutaneously in the right hind flank with 5 x10⁶ NCI-H292 cells and 5 x10⁶ SW620-luc cells suspended in 10% Matrigel in DMEM serum-free medium. After tumor size reached —150- to 200 mm3mice were randomized into groups (5 animals per group). Respective anti-EGFR antibody-drug conjugate was intravenously administered as a dose of 3 mg / kg, to the tail of each mouse for total of 3 doses, 1 week apart (start of dosing is referred to as Day 0 in the figures. Arrows indicate timing and frequency of dose administration). Phosphate buffer saline (PBS) was administered to the control group. Mean tumor volume was plotted until either the first death per group or end of the study. Error bars represent the standard error of the mean. FIG. 9 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 3 administration compared to vehicle control. 5 / 5 mice were tumor free in antibody drug conjugate Compound 3 group. FIG. 10 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 4 administration compared to vehicle control. 4 / 5 mice were tumor free in antibody drug conjugate Compound 4 group.Example 14: Tumor growth suppression effect on human lung adenocarcinoma cell line A549 of anti-EGFR antibody drug conjugates Compound 3 and Compound 4
[0131] A549 human lung adenocarcinoma cell line was purchased from ATCC. NOD- SCID mice (Charles River Labs, strain code #394), female, 7-8 weeks old were inoculated subcutaneously in the hind flank with 5 x10⁶ A549 cells suspended in 10% Matrigel in RPMI serum free medium. After tumor size reached -100 to 200 mm3 mice were randomized into groups (5 animals per group). Respective anti-EGFR antibody-drug conjugate was intravenously administered as a dose of 3 mg / kg (FIG. 11 and FIG. 12) or 10 mg / kg (FIG. 13 and FIG. 14) to the tail of each mouse for total of 4 doses, 1 week apart (start of dosing is referred to as Day 0 in the figures. Arrows indicate timing and frequency of dose administration). Phosphate buffer50IPTS / 200429160.1Atty. Docket No. SMO-005WOsaline (PBS) was administered to the control group. Mean tumor volume was plotted until either the first death per group or end of the study. Error bars represent the standard error of the mean. FIG. 11 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 3 administration compared to vehicle control at dose level 3 mg / kg, 4 doses. FIG. 12 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 4 administration compared to vehicle control at 3 mg / kg, 4 doses. FIG. 13 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 3 administration compared to vehicle control at 10 mg / kg, 4 doses. FIG. 14 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 4 administration compared to vehicle control at 10 mg / kg, 4 doses.Example 15: Tumor growth suppression effect on human lung mucoepidermoid carcinoma cell line NCI-H292 of anti-EGFR antibody drug conjugate Compound 4
[0132] NCI-H292 human lung mucoepidermoid carcinoma cell line was purchased from ATCC. NOD-SCID mice (Charles River Labs, strain code #394), female, 7-8 weeks old were inoculated subcutaneously in the hind flank with 5 x106A549 cells suspended in 10% Matrigel in RPMI serum free medium. After tumor size reached -100 to 200 mm3mice were randomized into groups (5 animals per group). Respective anti-EGFR antibody-drug conjugate was intravenously administered as a single dose of 10 mg / kg or 3 weekly doses of 3 mg / kg to the tail of each mouse (start of dosing is referred to as Day 0 in the figures). Arrows indicate timing and frequency of dose administration). Phosphate buffer saline (PBS) was administered to the control group. Mean tumor volume was plotted until either the first death per group or end of the study. Error bars represent the standard error of the mean. FIG. 15 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 4 administration compared to vehicle control at a single dose of 10 mg / kg. 5 / 5 mice were tumor free in antibody drug conjugate Compound 4 group. FIG. 16 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 4 administration compared to vehicle control at 3 mg / kg, 3 doses. 3 / 4 mice were tumor free in antibody drug conjugate Compound 4 group.Example 16: Tumor growth suppression effect on human pancreatic adenocarcinoma cell line CFPAC1 of anti-EGFR antibody drug conjugates Compound 4 and Compound 651IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0133] CFPAC1 human pancreatic adenocarcinoma carcinoma cell line was purchased from ATCC. Nu / Nu mice (Charles River Labs) female, 7-8 weeks old were inoculated subcutaneously in the hind flank with 5 x106CFPAC1 cells suspended in 10% Matrigel in RPMI serum free medium. After tumor size reached -100 to 200 mm3mice were randomized into groups (5 animals per group). Respective anti-EGFR antibody-drug conjugate was intravenously administered as 3 weekly doses of 1 mg / kg to the tail of each mouse (start of dosing is referred to as Day 0 in the figures). Arrows indicate timing and frequency of dose administration).Phosphate buffer saline (PBS) was administered to the control group. Mean tumor volume was plotted until either the first death per group or end of the study. Error bars represent the standard error of the mean. FIG. 17 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 4 administration compared to vehicle control. 3 / 5 mice were tumor free in antibody drug conjugate Compound 4 group. FIG. 18 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 6 administration compared to vehicle control. 4 / 5 mice were tumor free in antibody drug conjugate Compound 6 group.Example 17: Tumor growth suppression effect on human nasopharyngeal carcinoma cell line FaDu of anti-EGFR antibody drug conjugate Compound 6
[0134] FaDu human throat carcinoma cell line was purchased from ATCC. Nu / Nu mice (Charles River Labs) female, 7-8 weeks old were inoculated subcutaneously in the hind flank with 5 x106FaDu cells suspended in 10% Matrigel in EMEM serum free medium. After tumor size reached -100 to 200 mm3mice were randomized into groups (5 animals per group).Respective anti-EGFR antibody-drug conjugate was intravenously administered as 3 weekly doses of 1 mg / kg to the tail of each mouse (start of dosing is referred to as Day 0 in the figures). Arrows indicate timing and frequency of dose administration). Phosphate buffer saline (PBS) was administered to the control group. Mean tumor volume was plotted until either the first death per group or end of the study. Error bars represent the standard error of the mean. FIG. 19 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 6 administration compared to vehicle control. 5 / 5 mice were tumor free in antibody drug conjugate Compound 6 group.Example 18: Tumor growth suppression effect on human breast cancer cell line MDA-MB-468 of anti-EGFR antibody drug conjugate Compound 452IPTS / 200429160.1Atty. Docket No. SMO-005WO
[0135] MDA-MB-468 human breast cancer cell line was purchased from Accegen. NOD-SCID mice (Charles River Labs, strain code #394), female, 6-8 weeks old were inoculated subcutaneously in the hind flank with 5 x106MDA-MB-468 cells suspended in 10% Matrigel in serum-free medium. After tumor size reached -100 to 200 mm3mice were randomized into groups (5 animals per group). Respective anti-EGFR antibody-drug conjugate was intravenously administered as a dose of 1 mg / kg, once per week for a total of 3 doses to the tail of each mouse for 1 dose, start of dosing is referred to as Day 0 in the figures as indicated by the arrow.Phosphate buffer saline (PBS) was administered to the control group. Mean tumor volume was plotted until either the first death per group or end of the study. Error bars represent the standard error of the mean. FIG. 20 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 4 administration compared to vehicle control.Example 19: Tumor growth suppression effect on human breast cancer cell line MDA-MB-468 of anti-EGFR antibody drug conjugate Compound 6
[0136] MDA-MB-468 human breast cancer cell line was purchased from Accegen. Nu / Nu mice (Charles River Labs), female, 7-8 weeks old were inoculated subcutaneously in the hind flank with 5 x106MDA-MB-468 cells suspended in 10% Matrigel in serum-free medium. After tumor size reached -60 to 200 mm3mice were randomized into groups (5 animals per group). Respective anti-EGFR antibody-drug conjugate was intravenously administered as a dose of 1 mg / kg, once per week for a total of 3 doses to the tail of each mouse for 1 dose, start of dosing is referred to as Day 0 in the figures as indicated by the arrow. Phosphate buffer saline (PBS) was administered to the control group. Mean tumor volume was plotted until either the first death per group or end of the study. Error bars represent the standard error of the mean. FIG.21 shows mean tumor volume as a function of time after start of antibody drug conjugate Compound 6 administration compared to vehicle control.Example 20: Safety Pharmacology: Cardiovascular Safety Pharmacology with ECG Measurement
[0137] The potential for undesirable pharmacological activity of Compound 5 was assessed in the 6-week GLP repeat dose cynomolgus monkey toxicology study. Potential effects on the cardiovascular system were evaluated by incorporating ECG measurements during the53IPTS / 200429160.1Atty. Docket No. SMO-005WOpretreatment phase, once prior to the first dose, and on Day 1 and Day 43 (approximately 48 hours following dose administration), and at the end of recovery phase in all surviving animals. No abnormalities in rhythm or waveform morphology were found at any dose level and no Compound 5-related effects on the RR, PR interval, QRS duration, QT interval, or QTc interval were observed at doses up to 20 mg / kg.Example 21: Safety Pharmacology: hERG Assay with Released Payload Compound 1
[0138] The unconjugated payload Compound 1 was evaluated for its effect on the human ether-a-go-go related gene (hERG) potassium channel stably expressed in HEK293 cell line using manual patch-clamp technique. At concentrations of 1, 10 and 100 pM, Compound 1 produced 1.1%, 12.6%, and 36% inhibition of the hERG current amplitude, IC50value for the inhibitory effect of Compound 1 on hERG potassium current was greater than 100 pM (the highest concentration tested). The maximum concentration of 100 pM provides a ~ 23000-fold multiple to the ~ 4.4 nM Cmaxof the released Compound 1 in monkeys dosed with 20 mg / kg of Compound 5, the highest dose evaluated in the GLP toxicity study in monkeys and far exceeds the predicted Cmax(0.2 nM) for Compound 5 at the 1 mg / kg clinical start dose in patients.Example 22: Pharmacokinetic Studies
[0139] In a 6-Week repeat-dose (Q3W x 3) GLP toxicity study in monkeys at doses of 5, 10, and 20 mg / kg, the mean systemic exposure of Compound 5 Total ADC, Compound 5 total antibody, and Compound 1 (released payload) increased dose proportionally with increasing doses from 5 to 20 mg / kg. Compound 5 was tolerated at all doses evaluated. The 10 mg / kg dose was determined as the no-observed-adverse-effect-level (NOAEL), while the 20 mg / kg dose was determined as the Highest Non-Severely Toxic Dose (HNSTD).
[0140] Rat TK with Compound 1 showed increase in exposure (C0, AUC0-72, and AUC0-tau) with increasing dose in dose-proportional manner across dose range of 6 to 24 mg / kg. There were no meaningful sex differences in exposure, with no apparent accumulation across dose range of 6 mg / kg to 24 mg / kg, after the repeat dose. Mean plasma concentrations of Compound 1 declined immediately following dosing. The t1 / 2,agenerally ranged from 0.8-1.4 hours on Day 1 and Day 22. No trend towards accumulation was observed for Compound 1.54IPTS / 200429160.1Atty. Docket No. SMO-005WOExample 23: Distribution Studies
[0141] The binding of Compound 1 to proteins in plasma from human, monkey, mouse and rat were assessed in vitro at concentrations of 50 nM (27 ng / mL) and 200 nM (107 ng / mL) of Compound 1. In vitro assessment of Compound 1 demonstrated high plasma protein binding, with 98.8% in humans, 95.5% in monkeys, 93.6% in mouse, and 96.1% in rats.Example 24: Metabolism Studies
[0142] In vitro studies evaluating direct inhibition of and induction of cytochrome P450 enzymes by Compound 1 were conducted. No induction with up to 0.5 pM of Compound 1 or inhibition with up to 20 pM of Compound 1 of major drug metabolizing enzymes were observed. For example, inhibition of seven human cytochrome P450 enzymes (CYPs 1 A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4 isoforms) by Compound 1 was evaluated by measuring the in vitro metabolism of probe substrates. Incubations were performed in human liver microsomes with probe substrates and varying concentrations of Compound 1. The approach employed metabolite formation of probe substrates specific for each CYP isoform in human liver microsomes with NADPH and varying concentrations of Compound 1 from 0.02 pM to 20 pM. The well characterized, CYP-specific inhibitors were used as positive controls. IC50assay data for specific reversible and irreversible CYP inhibitors used as positive controls were within expected range based on literature. Compound 1 showed no evidence of inhibition, time dependent inhibition (TDI) or metabolite dependent inhibition (MDI) for any of the CYPs under the tested incubation conditions and highest concentration of 20 pM. Induction of the expression of cytochrome P450 (CYP) enzymes 1A2, 2B6 and 3A4 by Compound 1 at concentration range of 0.013 to 0.5 pM was assessed in human hepatocytes. Compound 1 did not cause CYP1A2, CYP2B6 or CYP3A4 activity and / or messenger ribose nucleic acid (mRNA) levels in human hepatocytes under the conditions used in this study.
[0143] Compound 5 was stable in human, monkey, rat, and mouse plasma. Compound 1 was identified as the one of the major and the most potent catabolites of Compound 5 in an EGFR-expressing tumor cell line, in human and monkey plasma, and in plasma of the monkeys dosed with Compound 5 in the repeat-dose exploratory toxicity study. In addition, the in vitro metabolic profiling of Compound 5 in human, monkey, rat and mouse hepatocytes showed55IPTS / 200429160.1Atty. Docket No. SMO-005WOcomparable catabolism pathway across all species, and no human specific metabolites were detected.INCORPORATION BY REFERENCE
[0144] All publications and patents mentioned herein are hereby incorporated by reference in their entirety for all purposes as if each individual publication or patent was specifically and individually incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.EQUIVALENTS
[0145] While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the present disclosure will become apparent to those skilled in the art upon review of this specification. The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
[0146] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present disclosure.56IPTS / 200429160.1
Claims
Atty. Docket No. SMO-005WOCLAIMSWhat is claimed is:
1. A method of treating a patient having advanced or metastatic solid cancer tumors, and in need thereof, comprising intravenously administering to the patient, once every two weeks or once every three weeks, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg. about 6 mg / kg, about 7 mg / kg, or about 8 mg / kg of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein:n is an integer or a decimal from 7 to 8; andL is an anti-EGFR antibody.
2. The method of claim 1, comprising administering the antibody-drug conjugate to the patient once every two weeks.
3. The method of claim 1, comprising administering the antibody-drug conjugate to the patient once every three weeks.
4. The method of any one of claims 1-3, comprising administering about 1 mg / kg, about 2 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, or about 8 mg / kg of the antibody-drug conjugate to the patient.
5. The method of any one of claims 1-4, comprising administering about 1 mg / kg of the antibody-drug conjugate to the patient.
6. The method of any one of claims 1-5, wherein the tumors are EGFR-expressing advanced or metastatic solid tumors.57IPTS / 200429160.1Atty. Docket No. SMO-005WO7. The method of any one of claims 1-6, wherein the tumor is one or more of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, colorectal cancer, cervical carcinoma, cutaneous squamous cell carcinoma, gastric cancer, ovarian cancer, pancreatic cancer, triple negative breast cancer, and urothelial transitional cell carcinoma.
8. The method of any one of claims 1-7, wherein the tumor is one of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer.
9. A method of treating a cancer selected from the group consisting of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer, in a patient in need thereof, comprising intravenously administering to the patient an effective amount of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein:n is an integer or a decimal from 7 to 8; andL is an anti-EGFR antibody.
10. The method of claim 9, comprising administering the antibody-drug conjugate to the patient once every two weeks.
11. The method of claim 9. comprising administering the antibody-drug conjugate to the patient once every three weeks.
12. The method of any one of claims 9-11, comprising administering about 1 mg / kg, about 2 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, or about 8 mg / kg of the antibody-drug conjugate to the patient.58IPTS / 200429160.1Atty. Docket No. SMO-005WO13. The method of any one of claims 9-12, comprising administering about 1 mg / kg of the antibody-drug conjugate to the patient.
14. A method of treating a cancer selected from the group consisting of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer, in a patient in need thereof, comprising intravenously administering to the patient, once every two weeks or once every three weeks, about 1 mg / kg, about 2 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, or about 8 mg / kg of an antibody-drug conjugate represented by:or pharmaceutically acceptable salt thereof, wherein:n is an integer or a decimal from 7 to 8; andL is an anti-EGFR antibody.
15. A method of treating a patient having advanced or metastatic solid cancer tumors selected from the group consisting of non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer, and in need thereof, comprising intravenously administering to the patient, once every two weeks or once every three weeks, an aqueous pharmaceutical composition formulated for intravenous administration comprising:about 10 mg / mL of an antibody-drug conjugate represented by:59IPTS / 200429160.1Atty. Docket No. SMO-005WOor pharmaceutically acceptable salt thereof, wherein n is an integer or a decimal from 7 to 8, and L is an anti-EGFR antibody;about 20 mM histidine;about 8% sucrose (w / v); andabout 0.02% polysorbate 80 (w / v);wherein the pH of the composition is about 5.5 at room temperature.
16. The method of claim 15, comprising administering about 1 mg / kg, about 2 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, or about 8 mg / kg of the antibody-drug conjugate to the patient.
17. The method of any one of claims 1-16, wherein L is selected from the group consisting of:an anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-Hl, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO:
1. SEQ ID NO:
4. and SEQ ID NO: 7, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 10, SEQ ID NO: 13, and SEQ ID NO: 16, respectively;an anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-Hl, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 2, SEQ ID NO: 5, and SEQ ID NO: 8, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 11, SEQ ID NO: 14, and SEQ ID NO: 17, respectively; and60IPTS / 200429160.1Atty. Docket No. SMO-005WOan anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 3, SEQ ID NO: 6, and SEQ ID NO: 9, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 12, SEQ ID NO: 15, and SEQ ID NO: 18, respectively.
18. The method of any one of claims 1-16, wherein L is selected from the group consisting of:an anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 19, SEQ ID NO: 23, and SEQ ID NO: 27, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 31, SEQ ID NO: 35, and SEQ ID NO: 39, respectively;an anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 20, SEQ ID NO: 24, and SEQ ID NO: 28, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 32, SEQ ID NO: 36, and SEQ ID NO: 40, respectively;an anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 29, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 33, SEQ ID NO: 37, and SEQ ID NO: 41, respectively; andan anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 22, SEQ ID NO: 26, and SEQ ID NO: 30, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 34, SEQ ID NO: 38, and SEQ ID NO: 42, respectively.
19. The method of any one of claims 1-16, wherein L is selected from the group consisting of:an anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 43, SEQ ID NO: 47, and SEQ ID61IPTS / 200429160.1Atty. Docket No. SMO-005WONO: 51, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 55, SEQ ID NO: 59, and SEQ ID NO: 63, respectively;an anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 44, SEQ ID NO: 48, and SEQ ID NO: 52, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 56, SEQ ID NO: 60, and SEQ ID NO: 64, respectively;an anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 45, SEQ ID NO: 49, and SEQ ID NO: 53, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 57, SEQ ID NO: 61, and SEQ ID NO: 65, respectively; andan anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 46, SEQ ID NO: 50, and SEQ ID NO: 54, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 58, SEQ ID NO: 62, and SEQ ID NO: 66, respectively.
20. The method of any one of claims 1-16, wherein L is selected from the group consisting of:an anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 67, SEQ ID NO: 70, and SEQ ID NO: 73, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 76, SEQ ID NO: 79, and SEQ ID NO: 82, respectively;an anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 68, SEQ ID NO: 71, and SEQ ID NO: 74, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 77, SEQ ID NO: 80, and SEQ ID NO: 83, respectively; and62IPTS / 200429160.1Atty. Docket No. SMO-005WOan anti-EGFR antibody comprising a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 sequences shown in SEQ ID NO: 69, SEQ ID NO: 72, and SEQ ID NO: 77, respectively; and a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3 sequences shown in SEQ ID NO: 78, SEQ ID NO: 81, and SEQ ID NO: 84, respectively.
21. The method of any one of claims 1-16, wherein L is selected from the group consisting of:an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 85, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 86;an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 87, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 88;an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 89, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 90;an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 91, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 92;an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 93, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 94; andan anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 95, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 96.
22. The method of any one of claims 1-16, wherein L is an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 85, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 86.63IPTS / 200429160.1Atty. Docket No. SMO-005WO23. The method of any one of claims 1-16, wherein L is an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 87, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 88.
24. The method of any one of claims 1-16, wherein L is an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 89, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 90.
25. The method of any one of claims 1-16, wherein L is an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 91, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 92.
26. The method of any one of claims 1-16, wherein L is an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 93, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 94.
27. The method of any one of claims 1-16, wherein L is an anti-EGFR antibody comprising a heavy chain consisting of an amino acid sequence shown in SEQ ID NO: 95, and a light chain consisting of an amino acid sequence shown in SEQ ID NO: 96.64IPTS / 200429160.1
